RU2565546C2 - Постоянные линии клеток человека для получения вирусов гриппа - Google Patents

Постоянные линии клеток человека для получения вирусов гриппа Download PDF

Info

Publication number
RU2565546C2
RU2565546C2 RU2013110786/10A RU2013110786A RU2565546C2 RU 2565546 C2 RU2565546 C2 RU 2565546C2 RU 2013110786/10 A RU2013110786/10 A RU 2013110786/10A RU 2013110786 A RU2013110786 A RU 2013110786A RU 2565546 C2 RU2565546 C2 RU 2565546C2
Authority
RU
Russia
Prior art keywords
cells
cell
influenza virus
virus
medium
Prior art date
Application number
RU2013110786/10A
Other languages
English (en)
Russian (ru)
Other versions
RU2013110786A (ru
Inventor
Гудрун ШИДНЕР
Удо РАЙХЛЬ
Original Assignee
Севек Фармасьютикалз Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Севек Фармасьютикалз Гмбх filed Critical Севек Фармасьютикалз Гмбх
Publication of RU2013110786A publication Critical patent/RU2013110786A/ru
Application granted granted Critical
Publication of RU2565546C2 publication Critical patent/RU2565546C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2013110786/10A 2010-08-16 2011-08-16 Постоянные линии клеток человека для получения вирусов гриппа RU2565546C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE102010037008.8 2010-08-16
DE102010037008 2010-08-16
DE102011050353 2011-05-13
DE102011050353.6 2011-05-13
PCT/DE2011/075194 WO2012041311A1 (de) 2010-08-16 2011-08-16 Permanente humane amniozyten zelllinie zur herstellung von influenzaviren

Publications (2)

Publication Number Publication Date
RU2013110786A RU2013110786A (ru) 2014-09-27
RU2565546C2 true RU2565546C2 (ru) 2015-10-20

Family

ID=44936126

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013110786/10A RU2565546C2 (ru) 2010-08-16 2011-08-16 Постоянные линии клеток человека для получения вирусов гриппа

Country Status (19)

Country Link
US (1) US20130344569A1 (enExample)
EP (1) EP2606128B1 (enExample)
JP (1) JP5928843B2 (enExample)
KR (1) KR101780257B1 (enExample)
CN (1) CN103168100B (enExample)
AU (1) AU2011307655B2 (enExample)
BR (1) BR112013003766B1 (enExample)
CA (1) CA2808453C (enExample)
DE (1) DE112011102737A5 (enExample)
DK (1) DK2606128T3 (enExample)
ES (1) ES2524894T3 (enExample)
IL (1) IL224728A (enExample)
MX (1) MX337687B (enExample)
PL (1) PL2606128T3 (enExample)
PT (1) PT2606128E (enExample)
RU (1) RU2565546C2 (enExample)
SG (1) SG187863A1 (enExample)
TW (1) TW201211257A (enExample)
WO (1) WO2012041311A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024537896A (ja) 2021-10-18 2024-10-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド アデノウイルス随伴ウイルスポリヌクレオチドを含む真核細胞
AR127674A1 (es) 2021-10-18 2024-02-21 Regeneron Pharma Células de mamífero que comprenden genes cas9 integrados para producir sitios de integración estables, y células de mamífero que comprenden sitios de integración estables y otros sitios
CN121343924A (zh) * 2024-07-15 2026-01-16 干细胞转化研究中心有限公司 极早期干细胞在流感病毒制备、检测和药物筛选中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU97121580A (ru) * 1995-05-26 1999-10-27 Эм Джи-Пи эм Си, Л.Л.Си. Способ получения гемагглютининовых поливалентных вакцин против гриппа
WO2002040665A2 (en) * 2000-11-15 2002-05-23 Crucell Holland B.V. Complementing cell lines
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
US7410798B2 (en) * 2001-01-10 2008-08-12 Geron Corporation Culture system for rapid expansion of human embryonic stem cells
DE19955558C2 (de) * 1999-11-18 2003-03-20 Stefan Kochanek Permanente Amniozyten-Zelllinie, ihre Herstellung und Verwendung zur Herstellung von Gentransfervektoren
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
ES2526170T3 (es) * 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
ES2402061T3 (es) * 2005-10-17 2013-04-26 Medimmune, Llc Método de aumento de la replicación del virus influenza
DE102005054628A1 (de) 2005-11-16 2007-05-24 Cevec Pharmaceuticals Gmbh Verfahren zur Herstellung von permanenten humanen Zelllinien
AU2007347716B2 (en) * 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU97121580A (ru) * 1995-05-26 1999-10-27 Эм Джи-Пи эм Си, Л.Л.Си. Способ получения гемагглютининовых поливалентных вакцин против гриппа
US20050170463A1 (en) * 1999-04-15 2005-08-04 Abraham Bout Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
WO2002040665A2 (en) * 2000-11-15 2002-05-23 Crucell Holland B.V. Complementing cell lines

Also Published As

Publication number Publication date
WO2012041311A1 (de) 2012-04-05
AU2011307655B2 (en) 2015-12-17
MX2013001772A (es) 2013-06-03
EP2606128B1 (de) 2014-09-10
ES2524894T3 (es) 2014-12-15
CA2808453C (en) 2020-05-05
CN103168100B (zh) 2016-04-13
IL224728A (en) 2016-05-31
CA2808453A1 (en) 2012-04-05
KR101780257B1 (ko) 2017-09-21
TW201211257A (en) 2012-03-16
PL2606128T3 (pl) 2015-02-27
SG187863A1 (en) 2013-03-28
EP2606128A1 (de) 2013-06-26
RU2013110786A (ru) 2014-09-27
KR20130097191A (ko) 2013-09-02
BR112013003766B1 (pt) 2021-08-24
JP5928843B2 (ja) 2016-06-01
JP2013537543A (ja) 2013-10-03
BR112013003766A2 (pt) 2016-05-31
CN103168100A (zh) 2013-06-19
AU2011307655A1 (en) 2013-03-21
US20130344569A1 (en) 2013-12-26
DE112011102737A5 (de) 2013-06-06
DK2606128T3 (en) 2014-12-01
MX337687B (es) 2016-03-15
PT2606128E (pt) 2014-12-09

Similar Documents

Publication Publication Date Title
KR100999345B1 (ko) Ｍｄｃｋ 세포 현탁 배양물 중에서 약물 또는 진단제 활성 성분의 생산 방법
US7504248B2 (en) Production of viruses viral isolates and vaccines
NO341506B1 (no) Høy titer rekombinante influensavira til vaksiner og genterapi
JP2005502357A (ja) 細胞培養物中のウイルス増殖
CN104812894B (zh) 新型mva病毒及其用途
CN110218706B (zh) 表达h7n9亚型高致病性禽流感病毒ha蛋白的重组火鸡疱疹病毒的构建与应用
Wen et al. Immunization by influenza virus-like particles protects aged mice against lethal influenza virus challenge
Liu et al. Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture
JP5928843B2 (ja) インフルエンザウイルスを製造するための永久ヒト羊膜細胞株
CN108888761B (zh) 表达h7n9亚型禽流感病毒血凝素蛋白的重组杆状病毒灭活疫苗及其制备方法与应用
CN119372158B (zh) 共同表达h9亚型aiv ha基因、ibv s基因和ibdv vp2基因的重组hvt及其应用
WO2018115308A1 (en) Method for purifying virus
US20190284577A1 (en) Ehv with inactivated ul18 and/or ul8
CN119351357B (zh) 一种表达h9亚型aiv ha基因和ibv s基因的重组火鸡疱疹病毒株及其应用
US8716016B2 (en) Immortal avian cell line and methods of use
AU2024234386A1 (en) Production of poxviruses from quail cell cultures
WO2024188801A1 (en) Use of quail cell lines for poxvirus production
Vázquez Ramírez Process intensification for the production of MVA and influenza A virus in high density suspension cultures of AGE1. CR. pIX cells
WO2024188802A1 (en) Methods of isolating poxviruses from avian cell cultures
Abdoli et al. Optimization of microcarrier-based MDCK-SIAT1 culture system for influenza virus propagation
Farnos et al. Development of a vaccine production platform for poultry diseases in Africa: Newcastle Disease Virus non-replicative adenovirus-vectored vaccine
Schwarzer et al. METABOLISM OF AVIAN DESIGNER CELLS DURING INFLUENZA AND MVA PRODUCTION

Legal Events

Date Code Title Description
HC9A Changing information about inventors
MM4A The patent is invalid due to non-payment of fees

Effective date: 20170817

NF4A Reinstatement of patent

Effective date: 20191028